Stock Price Prediction

BTMD stock has a bullish outlook with an average price target of $10.33, representing a potential upside of approximately 69% from its last close of $6.10. Analysts highlight strong financial performance, including a Q3 EPS beat of $0.33 versus $0.09 consensus, and strategic growth initiatives like integration with Asteria Health and Amazon partnerships. These factors, combined with robust demand in the dietary supplement segment, position BTMD for continued growth.

BTMD stock faces bearish sentiment due to its lowered FY24 revenue guidance ($197M-$201M) and underperformance compared to the S&P 500. Despite a Q3 earnings beat ($0.33 EPS vs. $0.09 consensus), the stock closed at $6.10, below the average analyst target of $10.33, signaling limited near-term upside. The reduced growth outlook and competitive pressures in the medical products industry weigh on its valuation.

The market consensus for BTMD's revenue in the upcoming quarter is projected to be approximately $53.478M USD.